ZBIO stock news
This page provides real-time market news, earnings updates, and company announcements related to Zenas BioPharma, Inc. (ZBIO).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-06-27 04:54 EST
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-02-20 21:18:06
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory
Finviz2026-02-28 15:57:50
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-16 11:03:45
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-03-16 22:06:42
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
Finviz2026-03-26 20:03:52
Zenas BioPharma Inc. recently announced that the proceeds from its financing will be specifically used to support the commercialization preparations of its core product, Obexelimab, in the US market.
老虎证券2026-03-26 20:06:25
Zenas BioPharma completes $300 million financing: issuance of convertible senior notes and common stock to accelerate autoimmune drug development Biopharmaceutical company Zenas BioPharma announced the completion of a concurrent public offering of 2.50% convertible senior notes due 2032 and common stock, raising a total of $300 million.
老虎证券2026-03-27 04:16:22
The Nasdaq Biotechnology Index maintains a gain of over 1.1%, after previously rising more than 1.4%.
华尔街见闻2026-05-04 15:50:59
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
Finviz2026-03-26 20:03:52
Zenas BioPharma Inc. recently announced that the proceeds from its financing will be specifically used to support the commercialization preparations of its core product, Obexelimab, in the US market.
老虎证券2026-03-26 20:06:25
Zenas BioPharma completes $300 million financing: issuance of convertible senior notes and common stock to accelerate autoimmune drug development Biopharmaceutical company Zenas BioPharma announced the completion of a concurrent public offering of 2.50% convertible senior notes due 2032 and common stock, raising a total of $300 million.
老虎证券2026-03-27 04:16:22
The Nasdaq Biotechnology Index maintains a gain of over 1.1%, after previously rising more than 1.4%.
华尔街见闻2026-05-04 15:50:59
ZBIO stock chart
ZBIO stock detailsZBIO stock price change
On the last trading day, ZBIO stock closed at 24.67 USD, with a price change of 13.17% for the day.
Trade spot stocks (24/7)Trade stock perps (up to 100x leverage)About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
To provide deeper liquidity, a more transparent trading experience, and greater capital efficiency, Bitget officially launched its all-new spot stock product, Bitget Stocks 2.0, on June 2, 2026.
The new product is independently issued by licensed RWA protocol Reality, with Bitget providing strategic support and asset security safeguards. This marks a major upgrade to the stock trading experience.
Bitget is moving stock trading beyond the limits of traditional trading models by fully integrating stock assets into its margin and yield ecosystem.
Learn more